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Abstract
Idiopathic Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the dysfunction of dopaminergic
dependent cortico-basal ganglia loops and diagnosed on the basis of motor symptoms (tremors and/or rigidity and
bradykinesia). Post-mortem studies tend to show that the destruction of dopaminergic neurons in the substantia nigra
constitutes an intermediate step in a broader neurodegenerative process rather than a unique feature of Parkinson’s
disease, as a consistent pattern of progression would exist, originating from the medulla oblongata/pontine tegmentum. To
date, neuroimaging techniques have been unable to characterize the pre-symptomatic stages of PD. However, if such a
regular neurodegenerative pattern were to exist, consistent damages would be found in the brain stem, even at early stages
of the disease. We recruited 23 PD patients at Hoenn and Yahr stages I to II of the disease and 18 healthy controls (HC)
matched for age. T1-weighted anatomical scans were acquired (MPRAGE, 1 mm3 resolution) and analyzed using an
optimized VBM protocol to detect white and grey matter volume reduction without spatial a priori. When the HC group was
compared to the PD group, a single cluster exhibited statistical difference (p,0.05 corrected for false detection rate, 4287
mm3) in the brain stem, between the pons and the medulla oblongata. The present study provides in-vivo evidence that
brain stem damage may be the first identifiable stage of PD neuropathology, and that the identification of this consistent
damage along with other factors could help with earlier diagnosis in the future. This damage could also explain some non-
motor symptoms in PD that often precede diagnosis, such as autonomic dysfunction and sleep disorders.
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Introduction
Idiopathic Parkinson’s disease (PD) is a neurodegenerative
disorder characterized by the progressive loss of dopaminergic
neurons of the subtantia nigra pars compacta, and clinically
diagnosed on the basis of a motor symptomatology: tremor,
rigidity and/or bradykynesia.
PD clinical diagnosis is particularly prone to errors [1,2], as this
array of motor symptoms is also present in a wide range of other
parkinsonian conditions such as progressive supranuclear palsy,
dementia with Lewy bodies, and multiple system atrophy.
Confirmation of the diagnosis is often brought by disease
progression and the response of patients to levodopa medication.
To date, in-vivo methods of brain imaging, CT-scan and
magnetic resonance imaging (MRI), have demonstrated little to no
sensitivity to PD. Recent analysis methods based on structural
MRI (T1-weighted contrast, diffusion tensor imaging [3]) have
been able to exhibit significant differences between demented and
non-demented PD patients [4,5], or between PD and PSP [6] or
dementia with Lewy bodies patients [7]. While these studies
brought some insight to the differential diagnosis of these various
diseases, they have been unable so far to clearly distinguish PD
patients from healthy controls [8,9].
Furthermore, post-mortem studies by Braak and colleagues
[10,11], based on the analysis of Lewy bodies and neurites
accumulation, a proteic hallmark of PD, have shown that various
cerebral structures are damaged before subtantia nigra in a
consistent and repeated pattern. They suggest that the diagnosis
temporal window of PD comes up to 10 years after the first
structural damages caused by the disease. In a 6 stages model [12],
PD would initially begin in the medulla oblongata and in the
olfactory bulb and progress in a caudorostral pattern, affecting
subtantia nigra in stage 3 only, corresponding to the onset of the
motor symptoms and the first visit of the patient to a neurologist.
Degeneration of pontine tegmentum nuclei antecedent to the death
of nigral dopaminergic neurons would generate a prior array of
non-motor symptoms, such as rapid eye movement sleep behavior
disorder (RBD), a condition that causes the loss of atonia during
sleep. RBD is incidentally found in more than half PD patients [13].
The aim of the present study is to characterize morphological
differences between PD patients at an early stage of the disease
and healthy controls using standard MRI scans and procedures. In
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observe damages across all PD patients localized in the brainstem,
the hypothesized initial location of the neurodegeneration. Voxel
based morphometry (VBM) is a technique that identifies local
atrophies without the subjective selection of an a priori region of
interest. Based on previous neuropathological findings, we
expected to observe brain tissue volume reduction in the medulla
oblongata/lower pontine tegmentum of PD patients compared to
healthy control subjects.
Methods
All participants gave informed consent to the protocol, which
was reviewed and approved by the Joint Ethics Committee of the
Regroupement Neuroimagerie Que ´bec (RNQ). Twenty-three
patients diagnosed with Parkinson’s disease participated in the
study, as well as 18 healthy controls matched for age. All PD
participants met the core assessment program for surgical
interventional therapy criteria for the diagnosis of idiopathic PD
[14,15] and the UK brain bank criteria for the diagnosis of
Parkinson’s disease [16]. Motor disability of individuals within the
PD group was in the mild to moderate severity range according to
the Hoehn and Yahr staging criteria [17]. The Montreal Cognitive
Assesment [18] was used to screen for early signs of dementia.
MRI Scanning
Participants were scanned using a 3T Siemens Trio MRI scanner
at the Functional NeuroimagingUnit, at the Research Center of the
Montreal Geriatric Institute (TR/TE/TI: 2300/2.91/900 ms, Flip
angle: 9u, 160 slices, field of view: 2566240 mm, matrix: 2566240,
voxel size: 16161 mm, 12-channels coil).
VBM analysis included two steps: spatial preprocessing
(normalization, segmentation, Jacobian modulation and smooth-
ing) and statistical analysis. Both steps were implemented in the
SPM software package [19] (Wellcome Department of Imaging
Neuroscience, London; http://www.fil.ion.ucl.ac.uk/spm) run-
ning on Matlab 7.3 (MathWorks, Natick, MA).
MRI images were pre-processed using an optimized standard
procedure [20]. A study-specific template and a priori images were
created by averaging all the anatomical scans that had been
normalized and segmented in the MNI (Montreal Neurological
Institute) stereotaxic space. A two-step segmentation procedure
was then applied to the scans in this analysis. First, T1-weighted
images were segmented in native space. Each grey/white matter
image was then normalized to the grey/white matter template.
The parameters obtained from the white-matter normalization
were then applied to the original T1 images. Finally, the
normalized images were segmented again into grey matter, white
matter and cerebrospinal fluid. White and grey matter voxel values
were multiplied by the Jacobian determinants derived from the
spatial normalization step (Jacobian modulation) to preserve the
initial volumes, to obtain modulated white matter images. These
images were then spatially smoothed with a 12 mm FWHM
isotropic Gaussian kernel. This kernel size was shown to minimize
the risk of false positive findings [21].
The normalized, segmented, and smoothed data were statisti-
cally tested using a general linear model based on gaussian field
theory using analysis of covariance, with age and gender of
participants and total amount of white matter (WM) or grey
matter (GM) volume treated as nuisance covariates to detect
regional areas of relative accelerated loss of WM or GM volume.
The statistical threshold was set at P,0.05, using false discovery
rate correction for multiple comparisons at the voxel level, and so
was the statistical threshold at the cluster level.
We applied the exact same methods to grey matter maps to
verify the absence of significant volume variation between the two
groups similarly to what has been previously reported in the
literature.
Results
A total of 23 PD patients (mean age=64.0265.47 years, 10
females, mean duration since first diagnosis=6.3363.93 years)
and 18 healthy controls (mean age=62.1765.40 years, no
significant differences with the PD group, 10 females) were
evaluated. The motor subset of the Unified Parkinson Disease
Rating Scale III was assessed to measure motor symptoms in the
PD group after a 12-hours withdrawal of anti parkinsonian
medication ( mean score=29.0768.97).
When comparing the modulated WM maps of the healthy
control with the PD group, a single symmetrical cluster was found,
in the caudal part of the pons, overlapping with the rostral medulla
oblongata (figure 1 and 2, volume=4287 mm3, peak coordinate
in the MNI space: -1, -36, 249, p,0.05 corrected for multiple
comparisons by false discovery rate, T score=6.40, Z score=5.17,
cluster significant at p,0.05 corrected for non-stationarity, note
that the peak survives a p,0.05 family-wise error statistical
threshold). No other cluster was found at that significance level, or
in the converse contrast.
We ran additional analyses to assess the effect of age in the tested
population. No cluster of significant atrophy survived at the
threshold used. At last, we ran analyses specific to the PD groups,
using age, gender, UPDRS-III score and duration of the disease
(expressed as the time elapsed between the first neurological
diagnosis and the MRI acquisition) as covariates, and found no
atrophy patterns. However, it should be noted that in the PD group,
at a low threshold of 0.001 uncorrected for multiple comparisons,
and no correction for cluster size, a symmetrical cluster of age-
related atrophy was observed in the middle corpus callosum.
Finally, in the GM maps, no significant differences were found
between the two groups even at a low threshold of 0.001
uncorrected for multiple comparisons.
Discussion
The goal of the study was to characterize the volume reduction
pattern in white matter associated with PD.
The key result is the finding of a single significant cluster of
white matter volume reduction, overlapping the rostral part of the
medulla oblongata and the caudal part of the pons. This finding is
consistent with the existence of a common anatomical starting
point of PD, in accordance with Braak et al. [10,12], unrelated to
the duration of the disease, or the severity in term of motor
impairments. This finding is also independent of age, although this
factor is known to interact with PD condition [22]. In the present
study, sub-threshold, age-related WM atrophy was noticed in the
PD group, but not in the brainstem.
White matter hyperintensities that have been observed
previously in anatomical MRI volumes of PD patients [23] are
known to cause segmentation errors. However, these hyperinten-
sities are bound to periventricular territories, and could not have
affected the findings of the present study.
Registration errors occurring during the normalization of
individual scans is a common criticism of the VBM method
[24], as voxels close on a spatial scale, but distant in term of
cerebral architecture (for instance, two different white matter
bundles spreading in one part and another of a sulcus) could be
merged during the analysis. However, the tubular geometric
nature of the brainstem preserves our result from this drawback.
Brain Stem Atrophy in PD
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matter region than the lower brain stem exhibiting signs of
atrophy at the group level. Since VBM analysis is a conservative
method, as no a priori region of interest is studied, we postulate
that damage in this region is common to all patients while the
regional evolution of the neurodegenerative process may be more
variable across PD patients, and hence lowers the sensibility of
white matter VBM analysis in other brain regions. It is also likely
that later stages of the disease affect grey matter more significantly
but in a more heterogeneous way. Indeed previous studies using
VBM in PD patients concentrated solely on grey matter and could
not find any significant differences with healthy individuals [8].
Our results on grey matter also confirm these findings.
It should be noted that the automatic segmentation algorithm
we used classifies brainstem as white matter, in spite of grey matter
presence. The result we observe should therefore be considered
with care, as an array of different microanatomical factors could
be at the origin of this decrease. Lewy bodies have been
historically considered as the hallmark of the disease [25], and
more recently, their presence in the substantia nigra has been
proposed to correlate with the motor scores of the UPDRS [26].
However, recent progresses in molecular biology and histo-
immunology suggest that alpha-synuclein deposits, which consti-
tute the main part of Lewy bodies, involve other cerebral
Figure 1. Localization of the atrophy. A. Schematic initial progression of Lewy body deposits in the first stages of Parkinson’s Disease, as
proposed by Braak and colleagues. B. Localization of the cluster of significant volume reduction in PD compared with HC. The significant cluster
located in the medulla oblongata/pons is superimposed as a red blob on the mean normalized anatomical scan of all participants. The axial and
sagital sections are centered on the peak of significance (21; 236; 249).
doi:10.1371/journal.pone.0008247.g001
Figure 2. Effect size at the peak of significance. Boxplot of the peak
of significance value (arbitrary unit) for each participant in both groups, as
obtained by SPM5 ‘fitted response’ plot function. Peak valuewas adjusted,
meaning that the effect of age, gender and global WM volume were
factored out, and only the effect of condition (Parkinson or Control) and
the residuals remained, as assessed by the SPM model. For each group,
bold line shows the median, central box includes the middle 50% of the
data, and tails of the boxplot show the minimum and maximum values.
doi:10.1371/journal.pone.0008247.g002
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oblongata, and that it should be considered as a more direct
measure of PD pathology and clinical symptomatology [27].
Finally, while we can not conclude regarding the white or grey
matter fine origin of the VBM decrease observed in this study, it
should also be noted that alpha-synuclein deposits has been shown
to affect white matter in the Multi-Systemic Atrophy [28].
In conclusion, to our knowledge, this is the first study
demonstrating that conventional T1-weighted 3 T MRI scans
can validate in vivo, on a group basis, the first stages of Braak’s
model [10–12], This key finding, based on conventional MRI
scans easily acquired in clinical practice, could define a critical
marker of the disease, in association with other biomarkers, for the
diagnosis of PD when initial symptomatology appears, but also
presymptomatically as other related symptoms occurs, such as
autonomic dysfunctions[29], RBD [13], or anosmia [30]. Future
studies should investigate the existence of a brain stem volumetric
reduction in related diseases, such as Lewy body dementia or other
forms of Parkinsonism. In order to validate the method further,
these studies should also be combined with methods that measure
the degree of dopamine denervation in those patients such as 11C-
DTBZ PET in North America [31] or DATscan in Europe. They
should also use larger population samples in association with
markers extracted from other MRI modalities (such as diffusion
tensor imaging, magnetization transfer ratio), in order to test the
diagnostic validity of the present finding in PD.
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